Jasper Therapeutics, Inc. — Q1 2023 Form 10-Q
Reporting period: Three months ended March 31, 2023. Jasper is a clinical-stage biotechnology company developing therapies targeting mast and hematopoietic stem cells. Its lead candidate, briquilimab, is being studied in several indications and as a conditioning treatment for stem-cell transplantation. The company has no approved products and generated no product-sales revenue.
Financial performance and liquidity
| Metric | Q1 2023 | Q1 2022 |
|---|---|---|
| Revenue | No product revenue | No product revenue |
| Research and development expense | $9.8 million | $8.2 million |
| General and administrative expense | $4.1 million | $4.6 million |
| Total operating expenses | $13.9 million | $12.8 million |
| Net loss | $14.3 million | $2.2 million |
| Basic and diluted loss per share | $0.16 | $0.06 |
| Cash used in operating activities | $10.3 million | $14.2 million |
- Cash and cash equivalents were $129.4 million at March 31, 2023, versus $38.3 million at December 31, 2022; total assets were $138.8 million and current liabilities were $7.9 million.
- Stockholders’ equity was $125.2 million and accumulated deficit was $119.4 million at quarter-end. The company reported no outstanding debt.
- Q1 financing provided $101.5 million net, principally from a January underwritten offering of 69.0 million shares ($96.9 million net) and ATM sales of 2.34 million shares ($4.5 million net). Shares outstanding rose from 38.0 million at year-end to 109.4 million at March 31.
- Margins are not meaningful because the company had no product revenue. Management expects existing cash to fund its operating plan for at least 12 months from the filing date, but says additional financing will be needed for continued development.
Changes versus the prior-year quarter
- Operating expenses increased 9%, with R&D up 20%, primarily reflecting higher manufacturing and validation costs, preclinical work, and R&D headcount. G&A declined 10% as lower consulting, recruiting, legal and insurance spending more than offset increased personnel costs.
- Net loss widened substantially, but the comparison was affected by non-cash fair-value movements: Q1 2022 included $4.6 million of earnout-liability gains and $6.1 million of warrant-liability gains; Q1 2023 recorded respective losses of $0.8 million and $0.6 million. The 2023 quarter also included $1.1 million of interest income.
- Operating cash use improved year over year, while the large financing inflow drove a $91.2 million increase in cash, cash equivalents and restricted cash.
Outlook, risks and notable items
- Management expects substantial ongoing losses and higher expenses as it advances clinical programs, funds manufacturing and research, and supports public-company operations. Profitability depends on successful development, regulatory approval and commercialization; no timing or certainty is provided.
- After quarter-end, Jasper’s new $250 million shelf registration became effective on May 5, 2023. The related ATM prospectus permits up to $75 million in stock sales; as of May 5, approximately $75 million remained available under the ATM and $175 million under the shelf. These are financing capacities, not committed proceeds.
- Key business risks include clinical-trial outcomes and timing, regulatory approval, manufacturing and supplier dependence, access to future capital, potential shareholder dilution, intellectual-property protection, and volatile stock prices. The filing also discusses possible financial-services disruptions and macroeconomic or geopolitical impacts.
- The $2.3 million CIRM grant is recorded as a liability because repayment may be required under certain circumstances; $50,000 remained available upon a future milestone. The earnout liability was $0.8 million at quarter-end and depends on stock-price milestones. No earnout trigger had occurred.
- The company reported no material pending legal proceedings. Management concluded disclosure controls were effective as of quarter-end.
Important facts for investors to verify
- Whether the stated cash runway remains adequate as trial, manufacturing and other R&D spending evolves, and when additional capital may be required.
- Clinical progress, enrollment, safety and efficacy evidence for briquilimab programs, including the SCID, MDS/AML and chronic-disease studies.
- Actual use of the shelf and ATM facilities, associated dilution, and the effect of future equity sales on existing shareholders.
- Manufacturing capacity, costs and continuity with contract manufacturers, as well as milestone obligations, licensing terms and potential CIRM repayment exposure.
- How much reported loss reflects underlying operating costs versus non-cash fair-value changes in warrants and earnout liabilities.